SIVOTEC and GENA Are Transforming Precision Medicine in South Florida Through AI and Genomics
In South Florida, a growing number of technology and healthcare companies are proving that the region can compete on a global stage in artificial intelligence, life sciences, and innovation. One company helping lead that movement is SIVOTEC, the Boca Raton-based company behind the AI-powered genomic platform, GENA.
At the intersection of healthcare, artificial intelligence, genomics, and data science, SIVOTEC is building technology designed to dramatically reduce the time it takes to identify rare genetic diseases and support the future of personalized medicine. What makes the company especially notable is not only the technology itself, but its commitment to building and growing the company in South Florida through partnerships with universities, researchers, students, and the broader innovation ecosystem.
Building Faster Answers Through AI and Genomics
SIVOTEC’s flagship platform, GENA, uses artificial intelligence and bioinformatics to help physicians, hospitals, laboratories, and researchers analyze genetic data more efficiently. The company’s mission is centered around accelerating diagnosis times, improving patient outcomes, and making precision medicine more accessible.
According to the company, the platform has already been used by more than 1,600 geneticists and has analyzed more than 160,000 genomic cases across over 40 countries.
GENA includes several tools tailored for different users in the healthcare ecosystem:
GENA Screen - designed to help physicians identify when genetic testing may be appropriate
GENA Test - helps geneticists and laboratories analyze genomic data more quickly
GENA Analysis - focused on predictive genomic mapping for patients
GENA PLM - a private language model being developed specifically for healthcare and biomedical intelligence
GENA Edu - education and workforce development initiative focused on training future healthcare and AI talent
The company says its AI-powered workflow can reduce genomic analysis times from days to seconds in certain use cases, helping physicians and geneticists make faster and more informed decisions.
The most impactful application of this type of AI-driven genomic analysis is in the early diagnosis of complex cases, where rapid interpretation can provide actionable intelligence for physicians. This enables more immediate clinical decision-making, improved patient care, and can significantly reduce unnecessary testing and associated healthcare costs.
“GENA has been used by approximately 1,600 geneticists around the world to help solve some of the most complex rare disease cases in pediatric and clinical genetics, particularly in situations where traditional diagnostic pathways can take years,” shared Pete Martinez, Chairman and CEO of SIVOTEC.
The Fragmentation Problem in Genomics
The genomics field has long been highly fragmented across laboratories, research institutions, and disconnected diagnostic tools. As a result, genetic data interpretation is often slow, inconsistent, and dependent on specialized expertise that is not widely available.
SIVOTEC was built in response to this structural gap.
Over the past several years, geneticists and physicians across multiple countries have used the GENA AI platform to help analyze complex genomic cases more efficiently within existing clinical workflows.
In the United States alone, there are approximately 3,500 practicing geneticists, while millions of patients are evaluated each year by non-geneticist physicians who often serve as the first point of contact for rare and undiagnosed diseases. This imbalance has made timely genetic interpretation one of the biggest bottlenecks in precision medicine.
AI is increasingly becoming a key enabling layer in addressing this challenge, particularly in helping bridge expertise gaps and accelerate early-stage diagnostic decisions.
According to the company, the GENA platform has supported analysis across more than 160,000 genomic cases spanning over 40 countries, contributing to one of the more widely applied AI-assisted genomic systems in use today.
Unlike general-purpose AI systems being adapted for healthcare use cases, SIVOTEC positions GENA as an expert-built system designed specifically for genomic medicine from the ground up, focused on workflow integration, clinical transparency, and structured decision support for healthcare professionals.
From Years to Seconds: The Human Cost of Rare Disease Diagnosis
For most parents, a medical diagnosis can take minutes. But for one Florida family, it took years.
In 2019, Jordan Avi Ogman was diagnosed with TECPR2, a rare and fatal neurodegenerative genetic disease. His family says it took nearly four years to reach that answer after repeated visits to doctors across South Florida.
“The worst thing was four years of not knowing,” said his father, David Ogman. “And us going to every doctor in South Florida trying to figure this out. They look at Jordan. They thumb through the physician’s desk reference. They say everything’s fine. Take him home. Every kid develops at their own pace.”
Like many families navigating rare disease cases, the path to diagnosis was long, uncertain, and emotionally exhausting. “They all pass away in their sleep from central sleep apnea. It’s a genetic brain disease, but it affects the entire central nervous system,” Ogman said.
The case highlights a broader challenge in healthcare: families often wait years for answers while diseases continue to progress, sometimes losing critical time when treatment options could still make a difference. “Unfortunately, we’re 4 years behind in developing the gene therapy… by the time it’s developed, Jordan might not be with us because we lost those 4 years,” Ogman said. David Ogman is also the Founder of the Jordan Avi Ogman Foundation.
Now, a Boca Raton-based company says technology may help change that timeline.
SIVOTEC’s GENA platform is designed to reduce genetic diagnosis timelines from years to seconds, using AI to accelerate how genetic data is analyzed and interpreted.
“We actually took the mind of a geneticist and put it into algorithms, and then accelerated the 3 to 4 days that it would take to diagnose one case, and we got it down to 10 seconds,” said Martinez.
The company says it has already helped analyze more than 160,000 rare disease cases and is working to expand access beyond geneticists to pediatricians and primary care physicians.
On average, patients with rare diseases still wait five to seven years for an accurate diagnosis. During that time, conditions can worsen, and in some cases, opportunities for intervention are lost.
As for Jordan’s family, they hope their experience can help prevent others from facing the same uncertainty. “If we had AI at our fingertips at any of these hospitals, Jordan would have been diagnosed immediately, and his cure would have already been developed,” Ogman said.
GENA Edu and Building the Next Generation of Talent
Beyond technology development, SIVOTEC is also investing heavily in education and workforce development through GENA Edu, the educational arm of the GENA platform.
GENA Edu was created to help bridge the gap between traditional healthcare education and the rapidly evolving fields of genomics, bioinformatics, artificial intelligence, and precision medicine. The initiative provides physicians, researchers, medical students, and university interns with hands-on access to genomic analysis tools and AI-powered healthcare technologies.
The program supports:
hands-on genomic analysis training
AI applications in healthcare
mentorship and internship opportunities
collaborative research initiatives
and continuing medical education (CME) programs for healthcare professionals.
The initiative aligns closely with SIVOTEC’s collaborations with the University of Miami’s UHealth and its engagement with interns and students from both Florida Atlantic University and the University of Miami. By creating opportunities for students to work directly with genomic datasets, healthcare AI systems, and real-world applications, the company is helping cultivate the next generation of biotech and health tech talent in South Florida.
At a time when the healthcare and genomics industries are facing growing talent shortages nationally, GENA Edu represents an effort to strengthen local workforce pipelines while keeping innovation rooted within the region.
Momentum and What’s Ahead
As adoption of the GENA platform continues to grow across clinical and research environments, SIVOTEC is increasingly being recognized as one of the emerging companies in AI-driven precision medicine.
The platform’s use across large-scale genomic datasets used across clinical and research settings and its expanding engagement with clinicians, researchers, and academic institutions reflect growing validation of its approach to accelerating rare disease diagnosis and improving clinical decision-making.
While the company remains focused on scaling its healthcare impact and expanding access to its technology, it is also entering a new phase of growth as it builds toward its next stage of institutional expansion and strategic investment.
SIVOTEC is expected to pursue a Series A raise in the near future as it continues to expand GENA’s clinical footprint, deepen academic partnerships, and scale its AI infrastructure for broader adoption across healthcare systems.
This next phase is centered on scaling impact, bringing faster genomic insight to more clinicians, more patients, and more healthcare systems globally.
A South Florida Collaboration with Global Potential
One of the defining aspects of SIVOTEC’s growth has been its collaboration with the University of Miami, particularly through the Frost Institute for Data Science and Computing (IDSC).
The relationship began in 2018 after founder Pete Martinez discovered research at the university that could help accelerate rare disease identification. SIVOTEC worked with the university’s Office of Innovation to license and integrate the technology into the GENA platform.
That partnership has continued to expand, with the University of Miami and SIVOTEC now collaborating on the development of GENA’s Private Language Model, a healthcare-focused AI system designed to securely analyze genetic, biomedical, and clinical data while protecting patient privacy.
University leaders have described the initiative as an example of how academia and industry can work together to shape the future of healthcare innovation. The collaboration brings together physicians, engineers, entrepreneurs, and researchers to develop new applications for AI-powered precision medicine.
At the same time, SIVOTEC has also leaned into talent development across South Florida, engaging with students and interns from both the Florida Atlantic University and the University of Miami. By involving students in research, data science, software engineering, and healthcare technology initiatives, the company is helping cultivate the next generation of local biotech and AI talent.
That focus reflects a broader trend happening across the region, where startups and innovation-driven companies are increasingly partnering with universities to build stronger pipelines between education, research, and industry.
Building a Health Tech Ecosystem in South Florida
SIVOTEC’s story is also part of a larger narrative unfolding across South Florida. As the region continues to grow as a destination for startups, healthcare innovation, AI, and research-driven companies, organizations like SIVOTEC demonstrate how local collaboration can create globally relevant technology.
By partnering with universities, investing in young talent, and building advanced healthcare platforms locally, the company is helping reinforce South Florida’s position as an emerging hub for biotech and applied artificial intelligence.
Rather than relocating innovation elsewhere, SIVOTEC is building from within the region, connecting academia, healthcare, and entrepreneurship to tackle some of medicine’s most complex challenges.
And as AI continues transforming healthcare worldwide, companies like SIVOTEC are showing that South Florida is not just participating in that future, but actively helping shape it.
